Cameron McDonough
Vorstandsvorsitzender bei GENERATION BIO CO.
Vermögen: 5 Mio $ am 30.04.2024
Aktive Positionen von Cameron McDonough
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENERATION BIO CO. | Direktor/Vorstandsmitglied | 01.10.2017 | - |
Vorstandsvorsitzender | 01.10.2017 | - | |
Präsident | 01.10.2017 | - | |
THIRD HARMONIC BIO, INC. | Direktor/Vorstandsmitglied | 28.03.2024 | - |
Independent Dir/Board Member | 28.03.2024 | - | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Berater | - | - |
Karriereverlauf von Cameron McDonough
Ehemalige bekannte Positionen von Cameron McDonough
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 22.02.2018 | 28.02.2022 |
Independent Dir/Board Member | 22.02.2018 | 28.02.2022 | |
PTC THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 06.11.2012 | 18.09.2017 |
Independent Dir/Board Member | 06.11.2012 | 18.09.2017 | |
SWEDISH ORPHAN BIOVITRUM AB | Vorstandsvorsitzender | 15.08.2011 | 22.05.2017 |
Präsident | 15.08.2011 | 22.05.2017 | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2002 | - |
Catalyst Medical Solutions, Inc. | Gründer | - | - |
Präsident | - | - | |
LARIMAR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.09.2015 | - |
Independent Dir/Board Member | 28.09.2015 | - |
Ausbildung von Cameron McDonough
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Harvard Medical School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
Schweden | 2 |
Operativ
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
President | 3 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
GENERATION BIO CO. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Catalyst Medical Solutions, Inc. |
- Börse
- Insiders
- Cameron McDonough
- Erfahrung